Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Back
7 Feb 2025
2:45 p.m.
3:15 p.m.
Brad
Rovin
Oral Abstract Presenter
United States
The Ohio State University